ArticleNeoplasia (New York, N.Y.)2011
Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
Article in Neoplasia (New York, N.Y.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 59 citations in OpenAlex.
- Urokinase Plasminogen Activator Deficiency Delays the Development of Obesity and Metabolic Sequelae.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Immune dysregulation drives the relapse of peritoneal dialysis-associated peritonitis: a single-center prospective study.Frontiers in immunology · 2026Article
- Single-cell transcriptomics reveals hypoxia-driven iCAF_PLAU is associated with stemness and immunosuppression in anorectal malignant melanoma.Journal of gastroenterology · 2025Article
- Remodeling the sarcoma microenvironment by simultaneous targeting of urokinase-type plasminogen activator receptors and epidermal growth factor receptors to promote antitumor activity.The Journal of pharmacology and experimental therapeutics · 2025Article
- MBsBMC cancer · 2025Article
- Urokinase Plasminogen Activator Receptor: An Important Focal Player in Chronic Subdural Hematoma?Inflammation · 2024Article
- Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics.NPJ precision oncology · 2024Article
- The Roles of Tumor-Associated Macrophages in Prostate Cancer.Journal of oncology · 2022Review
- Role of Serine Proteases at the Tumor-Stroma Interface.Frontiers in immunology · 2022Review
- The Plasminogen-Activator Plasmin System in Physiological and Pathophysiological Angiogenesis.International journal of molecular sciences · 2021Review
- uPAR: An Essential Factor for Tumor Development.Journal of Cancer · 2021Review
- Tumor angiogenesis: causes, consequences, challenges and opportunities.Cellular and molecular life sciences : CMLS · 2020Review
- Determination of urokinase-type plasminogen activator serum levels in healthy and oncologic cats.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2020Article
- D2A sequence of the urokinase receptor induces cell growth through αvβ3 integrin and EGFR.Cellular and molecular life sciences : CMLS · 2018Article
- Tumor microenvironment promotes prostate cancer cell dissemination via the Akt/mTOR pathway.Oncotarget · 2018Article
- Estramustine Phosphate Inhibits TGF-Analytical cellular pathology (Amsterdam) · 2018Article
- Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy.Frontiers in immunology · 2018Review
- Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer.International journal of nanomedicine · 2017Article
- GM-CSF and uPA are required for Porphyromonas gingivalis-induced alveolar bone loss in a mouse periodontitis model.Immunology and cell biology · 2015Article
- Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.Clinical & experimental metastasis · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Macrophages within the tumor microenvironment promote angiogenesis, extracellular matrix breakdown, and tumor cell migration, invasion, and metastasis. Activation of the urokinase plasminogen activator (uPA) and its receptor (uPAR) axis promotes prostate cancer tumorigenicity, invasion, metastasis, and survival within the tumor microenvironment. The link between macrophage infiltration and the uPA/uPAR axis in prostate cancer development has not been established, although it has been reported that uPA plays a critical role inmonocyte and macrophage chemotaxis. In this study, murine prostate cancer RM-1 cells were subcutaneously inoculated into wild-type (WT), uPA(-/-), and uPAR(-/-) mice. Tumor volume was significantly diminished in both uPA(-/-) and uPAR(-/-) mice compared with WT controls. Greater inhibition of tumor volume was also observed in uPA(-/-) mice compared with uPAR(-/-) mice, suggesting the important contribution of stromal-derived uPA to sustain the tumor growth. Immunohistochemical staining revealed that tumors in uPA(-/-) and uPAR(-/-) mice displayed significantly lower proliferative indices, higher apoptotic indices, and less neovascularity compared with the tumors in WT mice. Tumors in uPA(-/-) and uPAR(-/-) mice displayed significantly less macrophage infiltration as demonstrated by F4/80 staining and MAC3(+) cell numbers by flow cytometry compared with the tumors from WT mice. These findings suggest that the uPA/uPAR axis acts in both autocrine and paracrine manners in the tumor microenvironment, and activation of uPA/uPAR axis is essential for macrophage infiltration into prostate tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.